^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Testing whether prochlorperazine can be safely used to move anti-cancer therapy targets temporarily to tumour cell surfaces with combination dose increases of cetuximab anti-EGFR antibody.
Excerpt:
...TNBC patients: histologically confirmed tumour overexpression of EGFR...
Trial ID:
Source:
Title:
Radiation therapy using a fractionation modulated according to the pharmacokinetics of Cetuximab in squamous cell carcinoma head and neck cancer patient Trattamento radiante con frazionamento modulato in base alla farmacocinetica del Cetuximab nei pazienti con carcinoma squamoso del distretto cervico-facciale
Excerpt:
...- Pazienti con diagnosi istologica di carcinoma squamoso dell'orofaringe, laringe ed ipofaringe con indicazione a trattamento con radioterapia e Cetuximab a scopo curativo- Overespressione di EGFR (>50%)- PS (ECOG) ≤2- Pazienti con età > 18 anni- Consenso informato scritto - Patients with an histological diagnosis of squamous cell carcinoma of the oropharynx, larynx and hypopharynx eligible for a curative treatment with radiotherapy and Cetuximab - Overexpression of EGFR (> 50%)- PS (ECOG) ≤2- Age > 18 years- Written informed consent...
Trial ID:
Less C2 evidence
Source:
Title:
Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
Published date:
07/06/2020
Excerpt:
Studies of antitumor efficacy demonstrated that Cet-TPL drastically suppressed in vitro proliferation and in vivo growth of these EGFR-overexpressing cancers, including NSCLC A549 and H1299 cells and two patient-derived xenografts, and head and neck squamous carcinoma UM-SCC6 cell, while it did not inhibit the proliferation and growth of NSCLC H520 that rarely expresses EGFR...Taken together, Cet-TPL represents a potent targeting therapeutic agent against EGFR-overexpressing NSCLC and others...
DOI:
10.1016/j.omto.2020.07.001
